{"schema_version":"secwatch.filing_event.v1","accession":"0001551306-24-000199","form_type":"8-K","ticker":"PGNY","cik":"0001551306","company_name":"Progyny, Inc.","filed_at":"2024-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.763676+00:00","generated_at":"2026-05-30T01:51:47.428828+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Progyny Q3 revenue up 2% to $286.6M, net income falls 34% to $10.4M; cuts FY2024 guidance","bullets":["Revenue $286.6M (+2% YoY); net income $10.4M ($0.11 diluted EPS) vs $15.9M ($0.16) in Q3 2023.","Adjusted EBITDA $46.5M (-7.1% YoY); margin 16.2% vs 17.8% a year ago.","Full-year 2024 revenue guidance lowered to $1.135-1.150B; adjusted EBITDA guidance $189-194M.","New sales season adds 80+ clients, 1.1M new covered lives; also selected by two health plans as preferred partner.","Q3 utilization rate lower than expected; members took longer to progress, consuming fewer treatments."],"urls":{"canonical":"https://secwatch.observer/filing/0001551306-24-000199","json":"https://secwatch.observer/filing/0001551306-24-000199.json","markdown":"https://secwatch.observer/filing/0001551306-24-000199.md","text":"https://secwatch.observer/filing/0001551306-24-000199.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1551306/000155130624000199/0001551306-24-000199-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1551306/000155130624000199/pgny-20241112.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T01:51:47.428828+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}